The Excessive Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease

被引：12

作者：

Izquierdo Alonso, Jose Luis ^{[1
]}

Rodriguez Glez-Moro, Jose Miguel ^{[2
]}

机构：

[1] Hosp Univ Guadalajara, Serv Neumol, Guadalajara, Spain

[2] Hosp Gen Gregorio Maranon, Serv Neumol, Madrid, Spain

来源：

ARCHIVOS DE BRONCONEUMOLOGIA | 2012年 / 48卷 / 06期

关键词：

Chronic obstructive pulmonary disease (COPD); Inhaled corticosteroids; Efficacy; Safety; FLUTICASONE PROPIONATE/SALMETEROL 250/50; METERED-DOSE INHALER; MYOCARDIAL-INFARCTION; COPD EXACERBATIONS; DOUBLE-BLIND; RISK; BUDESONIDE; SALMETEROL; BUDESONIDE/FORMOTEROL; PROPIONATE;

D O I：

10.1016/j.arbres.2012.01.002

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Despite the fact that the recommendations of the main clinical guidelines have restricted the indications for inhaled corticosteroids in chronic obstructive pulmonary disease (COPD), currently more than 80% of patients are receiving this treatment in Spain, mostly with high doses. A detailed review of the literature does not justify the use of these high doses, a position that agrees with the recommendations of the FDA. A re-evaluation of their safety, the consistency of the data on their efficacy showing similar results with moderate doses and a better patient selection require the use of this treatment in COPD patients to be reconsidered. (C) 2011 SEPAR. Published by Elsevier Espana, S.L. All rights reserved.

引用

页码：207 / 212

页数：6

共 60 条

[1] Has the treatment of COPD changed in Spain?: Results of a community multicenter study (VICE) [J].

Alonso, J. L. Izquierdo ;

Gonzalez-Moro, J. M. Rodriguez ;

Ramos, P. de Lucas ;

Centeno, A. Martin ;

Vazquez, E. Gobartt .

REVISTA CLINICA ESPANOLA, 2008, 208 (01) :18-25

[2]

Altose MD, 2000, NEW ENGL J MED, V343, P1902

[3] Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes [J].

Anzueto, Antonio ;

Ferguson, Gary T. ;

Feldman, Greg ;

Chinsky, Kenneth ;

Seibert, Allan ;

Emmett, Amanda ;

Knobil, Katharine ;

O'Dell, Dianne ;

Kalberg, Christopher ;

Crater, Glenn .

COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2009, 6 (05) :320-329

[4] Clinical guidelines for diagnosing and treating chronic obstructive pulmonary disease [J].

Barberà, JA ;

Peces-Barba, G ;

Agustí, AGN ;

Izquierdo, JL ;

Monsó, E ;

Montemayor, T ;

Viejo, JL .

ARCHIVOS DE BRONCONEUMOLOGIA, 2001, 37 (06) :297-316

[5] Systemic manifestations and comorbidities of COPD [J].

Barnes, P. J. ;

Celli, B. R. .

EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (05) :1165-1185

[6] Inhaled Corticosteroids in COPD: A Controversy [J].

Barnes, Peter J. .

RESPIRATION, 2010, 80 (02) :89-95

[7] Glucocorticoid resistance in inflammatory diseases [J].

Barnes, Peter J. ;

Adcock, Ion M. .

LANCET, 2009, 373 (9678) :1905-1917

[8] Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].

Burge, PS ;

Calverley, PMA ;

Jones, PW ;

Spencer, S ;

Anderson, JA ;

Maslen, TK .

BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303

[9] Are inhaled corticosteroids systemic therapy for chronic obstructive pulmonary disease? [J].

Calverley, P .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (07) :721-722

[10] Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].

Calverley, P ;

Pauwels, R ;

Vestbo, J ;

Jones, P ;

Pride, N ;

Gulsvik, A ;

Anderson, J ;

Maden, C .

LANCET, 2003, 361 (9356) :449-456

← 1 2 3 4 5 6 →